key: cord-0939976-y9cjsd2g
authors: Edfors, Fredrik; Iglesias, Maria Jesus; Butler, Lynn M.; Odeberg, Jacob
title: Proteomics in thrombosis research
date: 2022-04-25
journal: Res Pract Thromb Haemost
DOI: 10.1002/rth2.12706
sha: 3ea13c0a080cbfa88843073fbabd997e536f2a3d
doc_id: 939976
cord_uid: y9cjsd2g

A State of the Art lecture titled “Proteomics in Thrombosis Research” was presented at the ISTH Congress in 2021. In clinical practice, there is a need for improved plasma biomarker‐based tools for diagnosis and risk prediction of venous thromboembolism (VTE). Analysis of blood, to identify plasma proteins with potential utility for such tools, could enable an individualized approach to treatment and prevention. Technological advances to study the plasma proteome on a large scale allows broad screening for the identification of novel plasma biomarkers, both by targeted and nontargeted proteomics methods. However, assay limitations need to be considered when interpreting results, with orthogonal validation required before conclusions are drawn. Here, we review and provide perspectives on the application of affinity‐ and mass spectrometry‐based methods for the identification and analysis of plasma protein biomarkers, with potential application in the field of VTE. We also provide a future perspective on discovery strategies and emerging technologies for targeted proteomics in thrombosis research. Finally, we summarize relevant new data on this topic, presented during the 2021 ISTH Congress.

Venous thromboembolism (VTE), comprising both deep vein thrombosis (DVT) and pulmonary embolism (PE) is a common, multicausal disease with serious short-term and long-term complications. It is associated with high mortality in the first year, especially within the first 30 days (~30% for PE) and a high risk of recurrence, with a cumulative incidence rate of 25% within 10 years. [1] [2] [3] [4] There is a workup includes assessment of clinical probability (e.g., using the Well score) in combination with measurement of the plasma biomarker D-dimers. 5, 6 Because of its low specificity for VTE, D-dimer is limited to ruling out VTE in low-probability cases, whereas diagnostic imaging is necessary to rule out or confirm diagnosis in medium-or high-probability cases. With less than 20% of computed tomography pulmonary angiograms performed on suspicion of PE confirming the diagnosis, 7-9 more specific biomarker-based tools implemented in the diagnostic workup have potential to reduce unnecessary imaging. Several studies have proposed biomarker candidates for acute VTE (e.g., p-selectin, microRNAs), 10 ing genetic variants contributing to VTE into such risk scores, including recently discovered common genetic variants, 17, 18 they still lack sufficient precision for individual risk prediction. 19, 20 This likely reflects the interplay between persistent and transient risk factors in VTE development, including genetics, acquired risk factors, and environmental exposures. 21 Blood plasma is an easily obtainable sample for analysis in a clinical setting that reflects active secretion, release, shedding, or leakage from cells and tissues in direct or indirect contact with blood. Because VTE is a disease of the intravascular compartment, the blood proteome could reflect combined environmental, genetic, and epigenetic contributors to risk variation between individuals.

However, compared with other disease states, a limited number of plasma proteomics studies has been reported, where novel biomarker candidates for VTE are identified. [22] [23] [24] [25] [26] [27] [28] [29] Today, several of the plasma proteins reportedly associated with VTE, and subsequently evaluated when incorporated into risk scores, have emerged from hypothesis driven analysis of a single, or limited set, of proteins based on known links to thrombosis (e.g., P-selectin 30 ). Systematic profiling of a larger portion of circulating plasma proteins could lead to discovery of novel protein biomarkers with potential clinical utility for VTE diagnosis and/or prediction. Recent technology developments in the proteomics field have made such high-throughput screening more accessible through commercial systems available as fee for service at core facilities and/or through commercial providers. Here, we will provide an overview of existing and emerging technologies and review the current literature on their relevance in VTE research and provide future perspectives.

Blood plasma is complex to analyze because of the very large concentration range (10 12 ) between most abundant (e.g., albumin, immunoglobulins) and least abundant (e.g., interluekin-6, interferon gamma) proteins. Indeed, less than 1% of the individual proteins found in plasma constitute more than 90% of the total protein concentration. [31] [32] [33] [34] Thus, analysis of the full protein profile in plasma, the circulating proteome, remains a challenge with currently available technologies. Today, analysis of the plasma proteome is typically performed using mass spectrometry (MS) or affinity-based methods.

MS-based methods inherently have a high specificity for detected proteins through direct identification of generated peptides, but the detection of low-abundance proteins remains challenging, and practical aspects limit sample throughput capacity. Affinity-based methods have gained popularity because of greater throughput capacity, multiplexity, small sample size, and reduced processing requirement (e.g., high abundance protein depletion or fractionation is not required), and a higher capacity than MS-based methods for the detection of low-abundance proteins. 33, 35, 36 Here, we will discuss the different approaches, their associated limitations, and the degree of consistency between the described platforms.

Affinity proteomics is based on the use of molecules (antibodies or aptamers) with specific binding capability to proteins of interest.

Over the years, affinity-based assays have moved from the detection a single protein at a time, as in Western blot or enzyme-linked immunosorbent assay (ELISA), to the measurement of large protein panels for the identification of signatures associated with specific disease conditions or health status. 31, 33, 35, 37 Here, we discuss the three in-solution technology platforms for large-scale screening of biomarker candidates that, to date, have been most commonly used for plasma proteomic analysis: the antibody-based suspension bead array (SBA), 38 the proximity extension assay (PEA), 39 and the aptamer-based SomaScan assay. 40 All three platforms allow for highly multiplexed profiling of proteins in many samples using a plate-based format. The conceptual principles of these methods are shown in Figure 1 .

The SBA technology is run on a commercial platform provided by Luminex Corp. (Austin, Texas, USA), which measures relative protein plasma levels using a flow cytometer-based analysis of multiplexed suspension bead arrays of protein-specific antibodies ( Figure 1A ).

The Luminex platform (FlexMAP3D) can analyze up to 500 proteins in 384 samples, using as little as 3 μl of plasma per sample run.

However, reliability depends on the specificity and functionality of antibodies used and any findings should be orthogonally validated.

Advantages, compared with the current PEA and aptamer-based platforms, include full flexibility in designing custom antibody panels in a scalable fashion. 33, 41 This technology platform has been used in proteomics studies for health assessment and various disease states, 33,42-44 including VTE. 22, 23 The PEA technology platform (Olink Proteomics AB, Uppsala, Sweden) uses selected paired antibodies, labeled with complementary DNA linkers, for the recognition of proteins ( Figure 1B) . A semiquantitative signal readout is generated either by quantitative polymerase chain reaction 39, 45, 46 or sequencing. 47 Conceptually, the application of dual antibodies targeting different neighboring epitopes increases specificity and reduces the risk that the signal reflects off-target binding. The unique sequences of the DNA linkers attached to the antibodies allow for a high level of multiplexing without the extensive cross-reactivity that would occur using conventional ELISAs. Still, differences in amplification efficacy and lack of quantitative standards mean that the measurements are semiquantitative and can only be used for relative comparisons of protein levels. PEA is commercially available as a high-throughput platform in a 96-plate format with multiplex immunoassays panels containing 48, 92, or 384 markers that are measured simultaneously.

The potential for agnostic interrogation of the plasma proteome to discover entirely novel biomarkers is somewhat limited by the reliance on predefined panels designed based on prior knowledge.

Currently, Olink offers 15 target panels (up to 92 protein markers/ panel) designed as "disease oriented" (e.g., cardiovascular panels) or pathway oriented (e.g., immune response, "cardiometabolic").

There is not a panel designed with a specific thrombosis/hemostasis focus, and a comprehensive interrogation of pathways and systems with known role or relevance for thrombosis requires the analysis of several different panels in combination (e.g., cardiovascular disease, cardiometabolic, cytokines). Four larger "exploratory panels" targeting approximately 1500 unique proteins have become available, with a focus on cardiometabolic-, oncology-, neurology-, and inflammation-associated biomarkers, and more recently a combined Explore 3072 panel targeting approximately 2950 unique proteins has been launched. This technology has been applied to biomarker profiling studies of VTE. [24] [25] [26] The aptamer-based SomaScan technology platform (Somalogic, Boulder, Colorado, USA) has emerged as an attractive alternative to antibody-based approaches 48 ( Figure 1C ). Whereas, like Olink, it relies on predefined panels, the most recent Somalogic platform 

In affinity proteomics, the signals generated cannot automatically be assumed to reflect target protein abundance because of potential for interference with the target/binder interaction ( Figure 2 ). 54 Antigen occlusion through posttranslational modifications, complex formation, differential splicing, or single nucleotide polymorphisms in the binding epitope can affect signal strength. Missense mutations directly affecting epitopes, or protein structure and binding accessibility, can affect the protein recognition in a manner in which genetic differences drive the associations, rather than protein levels. 55, 56 In addition, the measured signal can be generated by offtarget low-affinity binding of a high abundant protein, outcompeting the true target. 33 Compared with PEA/Olink, which rely on dual antibodies targeting two different epitopes, both SBA and SomaScan are conceptually more vulnerable to reporting off-target binding effects. Such effects can be highly platform and binder dependent because binders may target different regions of the protein and/or be differently affected by changes in protein structure. Furthermore, neither the SBA, PEA, or SomaScan technologies provide absolute quantitative protein concentrations, only relative values, and each on different scales. Thus, individual signals cannot be directly compared between different studies, even when assayed with the same assay panels. Therefore, for results obtained with affinity proteomics, orthogonal quantitative measurements (e.g., conventional

immunoassays, targeted quantitative MS) are needed to confirm an association between protein level and disease/phenotype. For example, immunoaffinity pulldown where the binder is coupled to magnetic beads and used to pull down the target from plasma before it is eluted, digested, and analyzed by liquid chromatography (LC)-MS, a method called immunocapture MS (IC-MS), can be F I G U R E 1 Affinity proteomics technologies. (A) Suspension bead array assay (Luminex): All proteins within the plasma sample are labelled with biotin for subsequent detection (A1) before incubation with a suspension of multiplexed protein-specific antibodies, each coupled to a unique color-coded micrometer-sized bead (A2). Unbound proteins are removed by washing and fluorescent-labeledstreptavidin is added to detect the protein biotin tag (A3). The suspension is analyzed by a cytometry-based instrument (Luminex), where the color of the antibody-bound bead provides the antibody identification, and the mean fluorescence intensity provides a relative measure of the corresponding target protein levels. (B) Proximity extension assay (Olink): for each biomarker, a matched pair of antibodies recognizing neighboring epitopes on the same target protein are linked to unique complementary oligonucleotides. Multiplex panels of matched antibody pairs are added to plasma (B1). When binding in close proximity on the protein target, the stretch of nucleotides hybridizes. DNA polymerase is added, and the annealing product is extended and amplified (B2) and detected by either quantitative polymerase chain reaction or next-generation sequencing (B3). The readout provides a relative measure of respective protein level in plasma. (C) SomaScan Assay (SomaLogic): for each biomarker, a single-stranded oligonucleotide, aptamer, folded into a tertiary structure, binds the target protein with affinity and specificity comparable to antibodies. The SomaScan platform is based on slow off-rate modified DNA aptamers (SOMAmers) labeled with a fluorescence reporter, photocleavage linker, and biotin. Multiplex panels of SOMAmers together with streptavidin coated beads bind respective target proteins in plasma (C1). Following washing to remove unbound proteins, fluorescent-labeled aptamer-protein complexes are released from the beads by ultraviolet-induced photocleavage, labeled with biotin (C2) and captured on fresh streptavidin-coated beads added to the sample, followed by washing to remove nonspecifically bound aptamers (C3). Protein-bound aptamers are released in denaturing buffer and detected by hybridization to complementary oligonucleotide probes on a microarray chip with the fluorescence intensity (C4) providing a relative measure of respective protein level in plasma. Figure created with BioRe nder.com used to technically validate the target of the binder ( Figure 3) . 54, 57 This can detect coenrichment of the target protein with other proteins, which can reflect complex binding with the intended target, cross-reactivity, or parallel on-target and off-target binding. Thus, identification of the intended target in IC-MS data does not exclude that a nontarget protein contributes to the signal associated to a trait or phenotype.

The most commonly used method for peptide identification when using MS is the shotgun proteomics strategy, which often is used for discovery studies. This unbiased method can measure more than 1000 proteins in plasma from single samples, using a peptide prefractionation strategy. 58 

Workflow for ImmunoCapture-mass spectrometry (IC-MS). Plasma samples are incubated with magnetic beads coupled with the affinity reagent (e.g., antibody). Beads with captured proteins are separated by applying a magnetic field, and nonbound proteins removed through sequential washes. Proteins bound to the antibody-coupled beads are digested with trypsin, and after bead removal, the resulting sample with peptide fragments are injected into liquid chromatography tandem MS for analysis. Figure created with BioRe nder.com rationale behind targeted proteomes, where specific and wellcharacterized ions are used to quantify a predefined set of peptides. One of these more targeted methods is the parallel reaction monitoring (PRM) ion sampling strategy, in which targeted acquisition is performed to simultaneously analyze all fragment ions of a preselected list of peptides. 65, 66 The more stringent type of targeted proteomics method is the selective reaction monitoring (SRM) strategy. 67 The SRM method demands a lot of preanalytical work spent at the assay generation stage, but when optimized, the assay can deliver excellent quantitative performance. The analytical method shows the highest degree of assay linearity, low limit of quantification, and high repeatability, which is in accordance with many existing clinical assays, making SRM particularly useful when studying a predefined set of proteins. 67, 68 To achieve absolute quantification, an accurately determined amount of a standard peptide (either as a peptide or as part of a protein), which is an isotopologue of the endogenous analyte of interest, is added to the sample as detailed previously.

for high-quality protein quantification in complex matrices, such as human blood plasma. 69 The method is an attractive alternative to many affinity-based methods because it can quantify proteins of interest without the need for any affinity reagent. The analytical strategy provides both high sensitivity, reproducibility, and quantitative performance over a broad dynamic range. 70 

Despite the identification of many possible biomarkers from studies using quantitative MS-based proteomics experiments, very few have made it to the clinic. Many quantitative, bottom-up proteomics workflows are affected by biases introduced throughout the sample preparation process, which includes protein denaturation, reduction, alkylation, digestion, and peptide separation, taking place upfront the mass analyzer. 61 This can be minimized through strict, standardized approaches 81 to limit variation and ensure high statistical significance when evaluating biomarkers of interest. 82, 83 However, systematic biases are introduced and are often accounted for by the introduction of stable isotope standards that are added directly to the sample of interest, which will act as a reference point of calibration. Addition at the peptide level cannot account for differences introduced at the digestion step, 84 but alternative strategies have been implemented. SIS guidelines can combat this, including flanked peptides (cleavable site), either by extension or by combining multiple protein targets combined into a single recombinant protein fragment (Quantification concatemer, QconCAT). 85 The most reproducible, but most expensive, alternative is a full-length SIS recombinant protein 86 ( Figure 4A ). This performance can be mimicked by the QPrESTs technology 87 where a shorter, 50 to 150 amino acid sequence that contains prototypic peptides can be spiked to the plasma instead ( Figure 4B ). In contrast to spiked peptides, spiked SIS proteins or protein fragments generate multiple proteotypic peptides to be added before the trypsin cleavage, ensuring that uncleaved endogenous peptides will not affect the quantification, as long as the digestion efficiency of the protein standard is the same as that of the endogenous protein target. Addition of PrESTs show very robust with interday coefficient of variations around 5%. 88 The PrEST technology has been used to quantify more than 100 proteins in human plasma 89 with addition-only protocols. This has introduced a new and more precise quantification rationale of proteins present in body fluids with good quantitative accuracy (<15%) 90 if compared with fully labeled protein standards.

Multiple studies have observed variable degrees of agreement between protein quantification in identical samples using dif- SomaScan assay, 20% and 35%, respectively, showed high Spearman correlation (rs ≥ 0.75), whereas 53% and 41% had low correlation (rs < 0.5), respectively, in the two sample sets. They also tested for association with acute kidney injury (AKI) using both methods; only about one-half of the AKI associations found using immunoassay data were replicated in the SomaScan data, with statistically significant differences in odds ratio for paired proteins generally found in the group of markers with low or medium correlations rs < 0.75.

AKI odds ratio tended to be observed when biomarkers had a higher plasma concentration, 52 suggesting that these platforms are more likely to replicate with concordance for abundant proteins, rather than those with than low abundance. proteins analyzed in the COPD cohorts were assessed for presence of cis pQTL to provide a measure of aptamer specificity for the respective target proteins. Of the 63 proteins, 31 (49%) had evidence of a cis pQTL in at least one of the two COPD cohorts, using data obtained with either of the two assays (SomaScan or immunoassays).

Targeted proteomics experiment using either spiked protein or peptide standards. (A) Stable isotope standards (SIS), incorporating an amino acid labeled with the stable isotopes, are added directly to the plasma sample prior to digestion. Alternatively, SIS peptides can be added upfront to liquid chromatography tandem mass spectrometry analysis. Target peptides are eluted and measured using selective reaction monitoring analysis. The endogenous (light) peptide concentration is calculated as a ratio between the heavy standard peptides of known concentration. A separate standard curve is established to define the dynamic range, limit of detection, and limit of quantification. (B) Illustration of the principle of SIS recombinant proteins (PrEST) as internal standards. SIS PrEST have amino acid sequences that uniquely align to the endogenous target protein. On tryptic digestion, proteotypic peptide fragments are released from the SIS PrEST and its target and the standard can be added upfront enzymatic digestion Furthermore, using public data, 42 (67%) were found to have a reported pQTL in either of two large studies. 56, 93 However, the median correlation in the subgroup of proteins with a pQTL (r = 0.5) was comparable to the overall correlation. Furthermore, they did not observe any systematic pattern for presence/absence of common missense variants among low-or high-correlating proteins. In general, presence of concordant cis pQTLs for a protein (suggestive of binding the annotated target) did not ensure high correlation across assays; however, discordant cis pQTLs were generally found only for low-correlating proteins. This indicates that although pQTL analysis is a useful tool to assess if a signal measures an on-target binding, further validation (e.g., orthogonal quantification of protein level) is necessary.

In a more recent study, Pietzner et al., 50 Table 1 .

We used multiplex antibody SBAs targeting 408 selected candidate proteins 22 study. 24 They identified five proteins as more specifically associated with an isolated PE phenotype compared with DVT or DVTassociated PE, of which three (interferonγ), glial cell-line derived neurotrophic factor, and interleukin-15Rα were replicated in Olink data from 5778 individuals in the Gutenberg Health Study. Target specificity for the corresponding Olink assays was validated using cis pQTL analysis. In a subsequent study, using the same Olink panels to analyze VTE patients sampled at diagnosis and at 12 months after the index event in GMP-VTE, they identified a body mass-associated proteomic signature of 11 proteins that were consistently related to body mass index in plasma of VTE patients sampled at diagnosis and at 12 months after the index event. 25 However, this signature did not explain the obesity paradox in VTE patients, but leptin was inversely associated with the combined endpoint of recurrent VTE and death. 

Mass spectrometry-based methods have been used to identify novel plasma biomarkers of acute atherothrombosis using a two-step approach of unbiased proteomic discovery analysis in a smaller sample set, followed by targeted validation of selected markers in a larger sample set. Shin et al. used LC-MS/MS in a discovery proteomics analysis of plasma from 50 patients with acute coronary syndrome (ACS) and 50 controls, followed by validation in 120 ACS and 120 controls by targeted MS proteomics for absolute quantification of seven Bruzelius et al., Blood 2016 22 This report describes the first large-scale affinity proteomics study in the venous thrombosis field. A total of 408 proteins are targeted in a discovery case/control study (VEBIOS, n = 88 cases and 85 controls) with validation in an independent case/control study (FARIVE, n = 580 cases, 589 controls). It describes the application of immuno-capture mass spectrometry to validate assay target specificity. Plasma level of platelet-derived growth factor β is identified as associated with venous thromboembolism risk.

Ten Cate et al., Blood 2021 24 This report describes the application of machine learning techniques to analyze affinity proteomics data. A total of 444 proteins are targeted in a discovery cohort (Genotyping and Molecular Phenotyping of Venous ThomboEmbolism, n = 532 cases) with validation in an independent population cohort (Gutenberg Health Study, n = 5778). It describes the application of cis pQTL analysis to validate assay target specificity. Plasma levels of interferonγ, glial cell-line derived neurotrophic factor, and interluekin-15Rα proteins are identified as associated with isolated pulmonary embolism.

This report describes an original integrated affinity proteomics and genetics strategy using a neural network approach, based on proteomics and genome-wide association studies data in the MARTHA study (n = 1388 cases) with replication in the EOVT study (n = 339 cases). PLXNA4 is identified as a new susceptibility gene for pulmonary embolism. biomarker candidates for vascular inflammatory disease that included 87 endothelium-related proteins predicted to be present in blood through in silico screening of public databases. 99 The SRM panel was used to analyze paired plasma samples from 23 and 29 patients with vasculitis before and after treatment, identifying nine markers that were validated by conventional ELISA in 169 patients. 99 with commercially available screening panels still primarily configured to detect proteins with known functions in pathophysiological processes and pathways involved in vascular disease. A significant number of candidates in such panels have wide tissue and/or cell type expression, which can complicate interpretation of pathophysiological relevance of identified markers. Indeed, a common feature of most clinically useful biomarkers is expression specificity to a particular tissue or cell type (e.g., plasma levels of a cardiac-specific isoform of intracellular troponin, such as TnT)

is used to detect protein leakage from injured cardiomyocytes in myocardial infarction. Indeed, the discovery of clinical biomarkers in use today typically followed the identification of the tissue-and/ or cell-specific expression patterns of the proteins. Developments in mRNA sequencing, of both tissue and single cells, has relatively recently transformed our understanding of the specificity of protein expression across the human body. 104 In the context of VTE research, the selection of potential candidate targets based on the discovery of their high specificity of expression in disease-relevant cell types, such endothelial cells 98 or others, 104 could uncover novel and more specific VTE biomarkers that could otherwise be missed by existing screening panels.

Mass spectrometry is the leading technology to accurately measure proteins in complex samples on a large scale. Targeted proteomics, in combination with the spike in stable isotope standards, is considered the gold standard and can improve both the analytical precision and specificity of the assay. The targeted proteomics workflow is very flexible and highly suitable for biomarker validation studies because it can report absolute protein concentrations, which can be compared across sites and studies. The combination of targeted proteomics and stable isotope standards are now robust enough for precision medicine efforts, where protein quantification must be reproducible over time. Technical leaps in chromatography allow for up to 100 proteomes to be quantified within 1 day, with hundreds of proteins quantified with median coefficient of variations less than 10% at an absolute scale. 89 These panels can be either be increased to cover a more comprehensive list of medium to high abundant plasma proteins, or tailored toward few biomarkers with high clinical significance.

The authors report no conflicts of interest.

All four authors participated in writing the manuscript and contrib- 

Jacob Odeberg @jac_ode

Incidence of venous thromboembolism in northern Sweden (VEINS): a population-based study

The epidemiology of venous thromboembolism

30-year mortality after venous thromboembolism: a populationbased cohort study

Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study

Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis

Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and ddimer

CT pulmonary angiography: an over-utilized imaging modality in hospitalized patients with suspected pulmonary embolism

How much overtesting is needed to safely exclude a diagnosis? A different perspective on triage testing using Bayes' theorem

D-Dimer use and pulmonary embolism diagnosis in emergency units: why is there such a difference in pulmonary embolism prevalence between the United States of America and countries outside USA? PLoS One

Diagnostic biomarkers in venous thromboembolic disease

Research progress on biomarkers of pulmonary embolism

Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model

Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH)

Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism

Functioning free latissimus dorsi muscle transplantation: anterogradely positioned usage in reconstruction of extensive forearm defect

Elevated D-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta-analysis

Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism

Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease

Current knowledge on the genetics of incident venous thrombosis

Inherited risk factors for venous thromboembolism

Environmental and genetic risk factors associated with venous thromboembolism

PDGFB, a new candidate plasma biomarker for venous thromboembolism: results from the VEREMA affinity proteomics study

An artificial neural network approach integrating plasma proteomics and genetic data identifies PLXNA4 as a new susceptibility locus for pulmonary embolism

Protein expression profiling suggests relevance of noncanonical pathways in isolated pulmonary embolism

A targeted proteomics investigation of the obesity paradox in venous thromboembolism

Identification of novel diagnostic biomarkers for deep venous thrombosis

Protein biomarkers for incident deep venous thrombosis in critically ill adolescents: an exploratory study

Discovery of novel plasma biomarkers for future incident venous thromboembolism by untargeted synchronous precursor selection mass spectrometry proteomics

Discovery of plasma biomarkers with data-independent acquisition mass spectrometry and antibody microarray for diagnosis and risk stratification of pulmonary embolism

Increased soluble Pselectin levels following deep venous thrombosis: cause or effect?

Aptamer-based multiplexed proteomic technology for biomarker discovery

Plasma Proteome Database as a resource for proteomics research: 2014 update

Genetics meets proteomics: perspectives for large population-based studies

The human plasma proteome: history, character, and diagnostic prospects

Bead-based assays for validating proteomic profiles in body fluids

Advances and utility of the human plasma proteome

Identification of endothelial proteins in plasma associated with cardiovascular risk factors

Highly multiplexed antibody suspension bead arrays for plasma protein profiling

Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood

Nucleic acid ligands with protein-like side chains: modified aptamers and their use as diagnostic and therapeutic agents

Affinity proteomics assays for cardiovascular and atherosclerotic disease biomarkers

Integration of molecular profiles in a longitudinal wellness profiling cohort

Whole blood co-expression modules associate with metabolic traits and type 2 diabetes: an IMI-DIRECT study

Targeted analysis of serum proteins encoded at known inflammatory bowel disease risk loci

Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability

Cytokine detection by antibody-based proximity ligation

Next generation plasma proteome profiling to monitor health and disease

The use of aptamers in large arrays for molecular diagnostics

aptamers they trust: the caveats of the SOMAscan biomarker discovery platform from SomaLogic

Synergistic insights into human health from aptamer-and antibody-based proteomic profiling

Soluble urokinase plasminogen activator receptor: genetic variation and cardiovascular disease risk in black adults

Comparison of proteomic methods in evaluating biomarker-AKI associations in cardiac surgery patients

Agreement of aptamer proteomics with standard methods for measuring venous thrombosis biomarkers

Systematic assessment of antibody selectivity in plasma based on a resource of enrichment profiles

Population-specific coding variant underlies genome-wide association with adiponectin level

Genomic atlas of the human plasma proteome

Aptamer-based proteomic profiling reveals novel candidate biomarkers and pathways in cardiovascular disease

Plasma proteome profiling to assess human health and disease

The implications of proteolytic background for shotgun proteomics

Identification and relative quantitation of protein mixtures by enzymatic digestion followed by capillary reversed-phase liquid chromatography-tandem mass spectrometry

Quantitative mass spectrometry in proteomics: a critical review

Automated approach for quantitative analysis of complex peptide mixtures from tandem mass spectra

Data-independent acquisition-based SWATH-MS for quantitative proteomics: a tutorial

Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis

Technical considerations for large-scale parallel reaction monitoring analysis

Parallel reaction monitoring (PRM) and selected reaction monitoring (SRM) exhibit comparable linearity, dynamic range and precision for targeted quantitative HDL proteomics

Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions

Perspectives of targeted mass spectrometry for protein biomarker verification

Advancing translational research and precision medicine with targeted proteomics

Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins

Method and platform standardization in MRM-based quantitative plasma proteomics

Minimal, encapsulated proteomic-sample processing applied to copy-number estimation in eukaryotic cells

Six decades searching for meaning in the proteome

MRMAssayDB: an integrated resource for validated targeted proteomics assays

Human SRMAtlas: a resource of targeted assays to quantify the complete human proteome

Proteogenomic analysis of human colon cancer reveals new therapeutic opportunities

Mass spectrometry-based proteomics

Protocol for standardizing high-to-moderate abundance protein biomarker assessments through an MRM-withstandard-peptides quantitative approach

Determination of the concentration range for 267 proteins from 21 lots of commercial human plasma using highly multiplexed multiple reaction monitoring mass spectrometry

Multiplexed targeted proteomic assay to assess coagulation factor concentrations and thrombosis-associated cancer

Highly reproducible automated proteomics sample preparation workflow for quantitative mass spectrometry

Recommendations for the generation, quantification, storage, and handling of peptides used for mass spectrometry-based assays

Revisiting biomarker discovery by plasma proteomics

Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma

QconCAT: internal standard for protein quantification

Isotope-labeled protein standards: toward absolute quantitative proteomics

A Protein Epitope Signature Tag (PrEST) library allows SILAC-based absolute quantification and multiplexed determination of protein copy numbers in cell lines

Absolute quantification of apolipoproteins following treatment with Omega-3 carboxylic acids and fenofibrate using a high precision stable isotope-labeled recombinant protein fragments based SRM assay

Targeted proteomics analysis of plasma proteins using recombinant protein standards for addition only workflows

Comparison of internal standard approaches for SRM analysis of alpha-synuclein in cerebrospinal fluid

Comparison of proteomic assessment methods in multiple cohort studies

Multiplatform approach for plasma proteomics: complementarity of Olink proximity extension assay technology to mass spectrometry-based protein profiling

Co-regulatory networks of human serum proteins link genetics to disease

Proteomics. Tissue-based map of the human proteome

Identification of haptoglobin as a potential diagnostic biomarker of acute pulmonary embolism

Serum biomarker discovery related to pathogenesis in acute coronary syndrome by proteomic approach

Characterization of differentially expressed plasma proteins in patients with acute myocardial infarction

Analysis of body-wide unfractionated tissue data to identify a core human endothelial transcriptome

Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis

Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study

Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH

Proteomic blood profiling in mild, severe and critical COVID-19 patients

American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19

A single-cell type transcriptomics map of human tissues

Proteomics in thrombosis research